PHARMING GROUP news, videos and press releases - Page 2
For more news please use our advanced search feature.
PHARMING GROUP - More news...
PHARMING GROUP - More news...
- Pharming Group announces the placement of €100 million convertible bonds due 2029
- Pharming Group announces the launch of an offering of approximately €100 million convertible bonds due 2029 and the concurrent repurchase of the outstanding €125 million convertible bonds due 2025
- Pharming announces completion of enrollment in pediatric clinical trial of leniolisib
- Pharming Group announces the 2024 Annual General Meeting of Shareholders
- Pharming Group announces the filing of its 2023 Annual Report and Form 20-F
- Pharming Group to participate in April investor conferences
- Pharming Group reports fourth quarter and full year 2023 financial results
- Pharming Group to report fourth quarter and full year 2023 financial results on March 14
- Pharming Group to participate in February investor conferences
- Pharming Group announces updated full year 2023 guidance and Joenja® U.S. launch update
- Pharming Group announces development plans for leniolisib for additional primary immunodeficiencies (PIDs)
- Pharming announces first patient dosed in pediatric clinical trial for children aged 1 to 6 years for leniolisib
- Pharming Group provides updates on EMA regulatory review of leniolisib MAA and plans to file for UK regulatory approval
- Pharming Group to participate in November investor conferences
- Pharming Group reports third quarter 2023 financial results
- Pharming Group to report third quarter 2023 financial results on October 26
- Pharming Group reports on results of the 2023 Extraordinary General Meeting of Shareholders
- Notice of First Quarter 2023 Results
- Pharming announces US FDA approval of Joenja® (leniolisib) as the first and only treatment indicated for APDS
- Pharming announces US FDA approval of Joenja® (leniolisib) as the first and only treatment indicated for APDS
- Pharming announces US FDA approval of Joenja® (leniolisib) as the first and only treatment indicated for APDS
- Pharming Group reports financial results for full year 2022
- Pharming Group announces that it expects to have full access today to its cash on deposit at Silicon Valley Bank Limited in light of UK Government announcement
- Pharming Group announces that it expects to have full access today to its cash on deposit at Silicon Valley Bank in light of US Government announcement
- Pharming Group issues statement regarding the events surrounding Silicon Valley Bank
- Notice of Full Year 2022 financial results
- Pharming announces first patient enrolled in pediatric clinical trial of leniolisib
- Pharming provides update on EMA regulatory review of leniolisib for APDS in Europe
- Pharming announces positive interim analysis data from open-label extension study of leniolisib in presentation at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition
- Pharming Group announces presentation of new leniolisib data at 2022 ASH Annual Meeting
